{"preliminary_commentary":{"by_channel":{"youtube":10,"podcast":8,"x_thread":7,"bluesky_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04564703\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"EMN26","nct_id":"NCT04564703","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=emn26-nct04564703. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Iberdomide will be given orally at 1.3 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.","label":"cohort 1","type":"EXPERIMENTAL"},{"description":"Iberdomide will be given orally at 1.0 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.","label":"cohort 2","type":"EXPERIMENTAL"},{"description":"Iberdomide will be given orally at 0.75 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.","label":"cohort 3","type":"EXPERIMENTAL"}],"collaborators":["Healt Data Specialists - HeaDS (CRO)","EMN Research Italy Impresa Sociale Srl"],"completion_date":{"date":"2027-12","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":160,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Iberdomide","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-16","lead_sponsor":"Stichting European Myeloma Network","official_title":"Phase II Study of Iberdomide (Cc220) Maintenance After Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2023-07-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Efficacy: rate of improvement in response with iberdomide maintenance after autologous stem cell transplantation (ASCT)","timeFrame":"6 months of treatment"},{"measure":"Rate of dose reductions/discontinuations with iberdomide maintenance after ASCT","timeFrame":"6 months of treatment"}],"references":[],"start_date":{"date":"2021-02-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients","url":"https://clinicaltrials.gov/study/NCT04564703"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/emn26-nct04564703"}